Giulia Costa

Giulia Costa

Auto-generated profile, based on publicly available information

Giulia Costa

Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RMRajagopal Murugan
Rajagopal Murugan
LBLisa Buchauer
Lisa Buchauer
GTGianna Triller
Gianna Triller
CKCornelia Kreschel
Cornelia Kreschel
GCGiulia Costa
Giulia Costa
HWHedda Wardemann
Hedda Wardemann
Affinity maturation, the clonal selection and expansion of antigen-activated B cells expressing somatically mutated antibody variants that develop during T cell–dependent germinal center reactions, is considered pivotal for efficient development of protective B cell memory responses to infection and vaccination. Repeated antigen exposure promotes affinity maturation but each time also recruits antigen-reactive naïve B cells into the response. Here, we determined the relative impact of affinity maturation versus antigen-mediated clonal selection of naïve B cells to mount potent B cell memory responses in humans after repeated exposure to a complex pathogen, the malaria parasite Plasmodium falciparum (Pf). Using single-cell immunoglobulin (Ig) gene sequencing and production of recombinant monoclonal antibodies, we analyzed the origin, development, and quality of memory B cell responses to Pf circumsporozoite protein (PfCSP), the major sporozoite surface protein. We show that after repeated immunization of Pf-naïve volunteers with infectious Pf sporozoites (PfSPZ Challenge) under chloroquine prophylaxis (PfSPZ-CVac), the clonal selection of potent germline and memory B cell precursors against the central PfCSP NANP repeat outpaces affinity maturation because the majority of Ig gene mutations are affinity-neutral. Mathematical modeling explains how the efficiency of affinity maturation decreases strongly with antigen complexity. Thus, in the absence of long-term exposure, the frequency of antigen-reactive precursors and likelihood of their activation rather than affinity maturation will determine the quality of anti-PfCSP memory B cell responses. These findings have wide implications for the design of vaccination strategies to induce potent B cell memory responses against PfCSP and presumably other structurally complex antigens.

22 June 2018 in Science
Verified
Journal Article
Open access
PDF file
KIKatharina Imkeller
Katharina Imkeller
SSStephen W. Scally
Stephen W. Scally
ABAlexandre Bosch
Alexandre Bosch
GMGemma Pidelaserra Martí
Gemma Pidelaserra Martí
GCGiulia Costa
Giulia Costa
HWHedda Wardemann
Hedda Wardemann
Surface antibody maturation: Affinity maturation in B cells generates antibodies with increasingly enhanced antigen-binding properties. Imkeller et al. investigated the maturation of human B cells that express protective antibodies against the circumsporozoite protein of the malaria-causing parasite Plasmodium falciparum (PfCSP). The repetitive structure of PfCSP induces mutations in B cells, facilitating direct interactions between two repeat-bound antibodies against PfCSP, which enhance antigen affinity and B cell activation. Such interactions may optimize binding and promote clustering of surface antibodies in general. Science , this issue p. 1358

27 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCG. Costa
G. Costa
MGM. Gildenhard
M. Gildenhard
MEM. Eldering
M. Eldering
RLR. L. Lindquist
R. L. Lindquist
AHA. E. Hauser
A. E. Hauser
ELE. A. Levashina
E. A. Levashina
Malaria is a fatal human parasitic disease transmitted by a mosquito vector. Although the evolution of within-host malaria virulence has been the focus of many theoretical and empirical studies, the vector’s contribution to this process is not well understood. Here, we explore how within-vector resource exploitation would impact the evolution of within-host Plasmodium virulence. By combining within-vector dynamics and malaria epidemiology, we develop a mathematical model, which predicts that non-competitive parasitic resource exploitation within-vector restricts within-host parasite virulence. To validate our model, we experimentally manipulate mosquito lipid trafficking and gauge within-vector parasite development and within-host infectivity and virulence. We find that mosquito-derived lipids determine within-host parasite virulence by shaping development (quantity) and metabolic activity (quality) of transmissible sporozoites. Our findings uncover the potential impact of within-vector environment and vector control strategies on the evolution of malaria virulence.

13 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ETElaine Thai
Elaine Thai
GCGiulia Costa
Giulia Costa
AWAnna Weyrich
Anna Weyrich
RMRajagopal Murugan
Rajagopal Murugan
DODavid Oyen
David Oyen
ELElena A. Levashina
Elena A. Levashina
Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we characterized the molecular recognition and functional efficacy of the N-CSP–specific monoclonal antibody 5D5. The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan. Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo. Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.

21 April 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
OOOpeyemi Ernest Oludada
Opeyemi Ernest Oludada
GCGiulia Costa
Giulia Costa
CAClare Burn Aschner
Clare Burn Aschner
AOAnna S Obraztsova
Anna S Obraztsova
KPKatherine Prieto
Katherine Prieto
HWHedda Wardemann
Hedda Wardemann
Human monoclonal antibodies (mAbs) against the central repeat and junction domain of Plasmodium falciparum circumsporozoite protein (PfCSP) have been studied extensively to guide malaria vaccine design compared to antibodies against the PfCSP C terminus. Here, we describe the molecular characteristics and protective potential of 73 germline and mutated human mAbs against the highly immunogenic PfCSP C‐terminal domain. Two mAbs recognized linear epitopes in the C‐terminal linker with sequence similarity to repeat and junction motifs, whereas all others targeted conformational epitopes in the α‐thrombospondin repeat (α‐TSR) domain. Specificity for the polymorphic Th2R/Th3R but not the conserved RII+/CS.T3 region in the α‐TSR was associated with IGHV3‐21 / IGVL3‐21 or IGLV3‐1 gene usage. Although the C terminus specific mAbs showed signs of more efficient affinity maturation and class‐switching compared to anti‐repeat mAbs, live sporozoite binding and inhibitory activity was limited to a single C‐linker reactive mAb with cross‐reactivity to the central repeat and junction. The data provide novel insights in the human anti‐C‐linker and anti‐α‐TSR antibody response that support exclusion of the PfCSP C terminus from malaria vaccine designs.

16 April 2026 in Science
Verified
Journal Article
Closed access
HHHarald Hartweger
Harald Hartweger
CRChiara Ruprecht
Chiara Ruprecht
KYKai-Hui Yao
Kai-Hui Yao
PLPhilippe Laffont
Philippe Laffont
GRGabriella Lima Dos Reis
Gabriella Lima Dos Reis
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Long-term in vivo production of therapeutic proteins and development of vaccines that elicit protective levels of broadly neutralizing antibodies (bNAbs) against major pathogens face challenges. In this study, we report on an alternative gene editing approach using small numbers of hematopoietic stem and progenitor cells (HSPCs) to direct long-term, high-level expression of antibodies or cargo proteins. In mice, edited B lymphocytes derived from transplanted HSPCs were activated by cognate antigen, underwent clonal expansion, and developed into specific antibody-synthesizing or cargo protein–synthesizing plasma cells. These cells produced long-lasting, therapeutic levels of serum antibody against HIV-1, malaria, or an anti-influenza virus bNAb that mediated universal protection from heterologous lethal challenge. Our data provide a paradigm for cell therapy approaches to prevent or treat disease using self-amplifying B cell protein factories.